Bipolar disorder (children) - aripirazole: evaluation report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Bipolar disorder (children) - aripiprazole: evaluation report
01. Pre Meeting Briefing prepared by NICE
02. Submission from the technology manufacturer - Otsuka Phrmaceuticals
03. NICE request to the manufacturer for clarification on their submission
04. Manufacturer's clarification response
05. Consultee Submission - British Association of Psychopharmacology
06. Consultee Submission - Royal College of Nursing
07. Consultee Submission - Royal College of Paediatrics and Child Health
09. Clinical Expert personal perspective - James
10. Clinical Expert personal perspective - Coghill
11. Evidence Review Group Report prepared by School of Health Related Research
12. Evidence Review Group report - factual accuracy check
13. Evidence Review Group report - factual accuracy check corrections
Bipolar disorder (children) - aripirazole: evaluation report
07 June 2013 (8.48 Mb 10 sec) |
This page was last updated: 06 June 2013